Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Merck KGaA

Start price
Target price
Perf. (%)
€184.15
09.08.21
-
09.08.22
-1.52%
26.03.22

ROE higher than 10% per year
Low dividend yield expected
buy
Bayer AG

Start price
Target price
Perf. (%)
€57.80
18.03.22
-
18.03.23
4.83%
25.03.22

buy
Bayer AG

Start price
Target price
Perf. (%)
€57.80
18.03.22
-
18.03.23
4.83%
25.03.22

buy
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.015
20.02.22
€7.50
20.03.22
61900.00%
21.03.22

Could be worthwhile Investment >10% per year
buy
Agios Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€25.74
20.02.22
€30.00
20.03.22
2.76%
21.03.22

Could be worthwhile Investment >10% per year
buy
Poxel S.A.

Start price
Target price
Perf. (%)
€3.04
20.02.22
€4.00
20.03.22
-11.39%
21.03.22

Could be worthwhile Investment >10% per year
Kala Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€81.03
15.03.22
-
15.03.23
-14.84%
20.03.22

Could be worthwhile Investment >10% per year
buy
Bayer AG

Start price
Target price
Perf. (%)
€56.99
17.03.22
-
17.03.23
1.42%
18.03.22

buy
Bayer AG

Start price
Target price
Perf. (%)
€56.99
17.03.22
-
17.03.23
1.42%
18.03.22

Aphria Inc.

Start price
Target price
Perf. (%)
€12.71
20.02.22
€13.00
20.02.23
-
17.03.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€13.20
06.03.22
-
06.03.23
17.35%
17.03.22

Risky Investment
Novocure Ltd

Start price
Target price
Perf. (%)
€59.26
09.01.22
€51.00
09.01.23
8.34%
16.03.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€20.53
14.03.22
€14.00
14.03.23
3.70%
16.03.22

Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
buy
Chemocentryx Inc.

Start price
Target price
Perf. (%)
€30.25
13.10.21
€34.00
30.07.22
-32.13%
14.03.22

Lower EBIT Margin than peer group
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€5.39
30.01.22
€4.00
30.01.23
-10.83%
14.03.22

Standard Investments for future growth
Higher EBIT margin than peer group
Very low/no dividend yield expected
ROE lower than 10% per year
buy
Novo Nordisk A/S

Start price
Target price
Perf. (%)
€98.92
09.11.21
-
09.11.22
-5.03%
13.03.22

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€470.00
13.10.21
-
13.10.22
24.89%
13.03.22

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€470.00
13.10.21
-
13.10.22
24.89%
13.03.22

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€470.00
13.10.21
-
13.10.22
24.89%
13.03.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€37.80
23.09.21
-
23.09.22
22.31%
13.03.22

buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€37.80
23.09.21
-
23.09.22
22.31%
13.03.22

buy
QIAGEN NV

Start price
Target price
Perf. (%)
€47.17
09.09.21
-
09.09.22
-13.08%
13.03.22

buy
QIAGEN NV

Start price
Target price
Perf. (%)
€47.17
09.09.21
-
09.09.22
-13.08%
13.03.22

buy
Catalyst Pharmaceutical Partners Inc

Start price
Target price
Perf. (%)
€4.66
12.07.21
-
12.07.22
48.95%
13.03.22

buy
Avid Bioservices Inc

Start price
Target price
Perf. (%)
€18.30
09.02.22
€20.00
09.03.22
-7.10%
10.03.22

Could be worthwhile Investment >10% per year